EULAR 2018 Highlights
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Notes<br />
Saturday, June 16, <strong>2018</strong><br />
POSTER TOURS<br />
Poster Tour S5: Breakout news on non-TNF<br />
biologics in RA<br />
Poster Area – 10:30 - 12:00<br />
SAT0165<br />
Reasons for bDMARD Cessation and Subsequent<br />
Persistence of Second Line Treatment in a Large<br />
Real World Rheumatoid Arthritis Registry<br />
Poster Tour S6: Novel insights on nonbiologics<br />
in RA<br />
Poster Area – 10:30 - 12:00<br />
SAT0217<br />
<br />
SAT0218<br />
<br />
SAT0219<br />
<br />
SAT0220<br />
<br />
ABSTRACT ONLY<br />
AB0046<br />
<br />
Identification of Distinct Disease Activity<br />
Trajectories in Patients with Rheumatoid Arthritis<br />
Receiving Tofacitinib over 12 Months<br />
Efficacy and Safety of Baricitinib in MTX-IR<br />
Patients with Rheumatoid Arthritis: 52 Week<br />
Results from a Phase 3 Study (RA-BALANCE)<br />
Upadacitinib in Patients with Active Rheumatoid<br />
Arthritis and Inadequate Response or Intolerance<br />
to Biological DMARDs: A Phase 3 Randomized,<br />
Placebo-Controlled, Double-Blind Study of a<br />
Selective JAK1 Inhibitor<br />
Evaluation of Live Zoster Vaccine in a Subset of<br />
Patients with Rheumatoid Arthritis Treated with<br />
Tofacitinib with or without Methotrexate, and<br />
Adalimumab with Methotrexate: Results from a<br />
Phase 3b/4 Randomised Trial<br />
Tofacitinib Impairs Monocyte-Derived Dendritic<br />
Cell Differentiation in Rheumatoid Arthritis and<br />
Psoriatic Arthritis<br />
AB0210<br />
AB0240<br />
AB0258<br />
<br />
AB0282<br />
AB0413<br />
AB0425<br />
AB0478<br />
AB0479<br />
AB0482<br />
AB0484<br />
Clinical and Musculoskeletal Ultrasound<br />
Assessment of Therapeutic Response to<br />
Tofacitinib in Patients with Rheumatoid<br />
Arthritis: Real-World Clinical Experience from<br />
a Single Center in Hong Kong<br />
Reduction in Fatigue and Pain are Associated with<br />
Improved Work Productivity in Patients with RA<br />
Impact of Controlling Disease Activity on<br />
Regaining Normal Physical Function, and<br />
Achieving No or Limited Pain in Patients with<br />
Rheumatoid Arthritis Treated with Baricitinib<br />
Adjusting the Dose of Tofacitinib to Achieve<br />
Optimal Results in the Management of Patients<br />
with Active Rheumatoid Arthritis (RA) May<br />
Offer More Successful Results than Utilizing a<br />
Standard Fixed One Dose Approach<br />
Nodular Polyarteritis as an Unforeseeable Adverse<br />
Reaction in RA Patient Treated with Tofacitinib<br />
Prevalence and Risk Factors of Serious<br />
Infections in Rheumatoid Arthritis Patients<br />
Receiving the Biologic/Targeted Synthetic<br />
DMARDs: A Propensity Score Analysis from the<br />
Hong Kong Biologics Registry<br />
Mild and Moderate Hepatic Impairment Have<br />
No Clinically Relevant Impact on Upadacitinib<br />
Pharmacokinetics: Results from a Dedicated<br />
Phase 1 Study<br />
Characterization of the Effect of Renal<br />
Impairment on Upadacitinib Pharmacokinetics<br />
Similar Efficacy of Tofacitinib on Disease<br />
Activity in Rheumatoid Arthritis Patients with<br />
and without Previous Biologicals; Results from<br />
the Turkbio Registry<br />
Monotherapy with Filgotinib, A JAK1-Selective<br />
Inhibitor, Reduces Disease Severity and Alters<br />
Immune Cell Subsets in the NZB/W F1 Murine<br />
Model of Lupus<br />
AB0485<br />
<br />
AB0489<br />
<br />
AB0492<br />
AB0495<br />
AB0497<br />
AB0500<br />
AB0502<br />
AB0902<br />
<br />
AB0920<br />
AB0921<br />
<br />
Comparative Efficacy of Tofacitinib and Biologic<br />
DMARDs in Patients with Rheumatoid Arthritis<br />
with Insufficient Response to Subcutaneous<br />
Methotrexate in Clinical Practice<br />
Tofacitinib Improves Left Ventricular Mass and<br />
Cardiac Output in Rheumatoid Arthritis Patients<br />
with Chronic Heart Failure<br />
JAK-Inhibition with Peficitinib and Filgotinib in<br />
Fibroblast-Like Synoviocytes in Rheumatoid Arthritis<br />
Post-Marketing Surveillance of Tofacitinib in<br />
Japanese Patients with Rheumatoid Arthritis: An<br />
Interim Report of Safety Data<br />
Effectiveness, Tolerability, and Safety of<br />
Tofacitinib in Rheumatoid Arthritis: A<br />
Retrospective Analysis of Real-World Data from<br />
the St. Gallen And Aarau Cohort<br />
Efficacy and Safety of Tofacitinib (Tof) in<br />
Patients with Rheumatoid Arthritis at 52 Weeks<br />
in Clinical Practice<br />
Drug Survival Analysis of Tofacitinib in Patients<br />
with Rheumatoid Arthritis<br />
Efficacy of Tofacitinib by Background<br />
Methotrexate Dose in Patients with Psoriatic<br />
Arthritis: A Post-Hoc Analysis of Pooled Data<br />
from 2 Phase 3 Trials<br />
Tumor Necrosis Factor Inhibitors Persistence in<br />
Psoriatic Arthritis Patients<br />
Impact of Baseline Demographics, Disease<br />
Activity and Concomitant Medication on<br />
American College of Rheumatology 20 Response<br />
Rate and Health Assessment Questionnaire-<br />
Disability Index Score with Tofacitinib in Active<br />
Psoriatic Arthritis: A Pooled Subgroup Analysis of<br />
2 Phase 3 Studies<br />
Chairman’s picks<br />
Chairman’s picks
Change language